About

Based in Bonn, Germany, CARDIONOVUM is focused on developments of truly innovative peripheral and cardiovascular medical devices: specifically, next-generation drug-coated balloon (DCB) and stent technologies, to improve the quality of life of patients. Founded in 2010 by CEO and CTO, Dr Michael Orlowski, CARDIONOVUM has marketing activities in more than 40 countries worldwide. Dr Orlowski is the pioneer of DCB catheters and was the first to obtain CE-marking approval for a DCB, which was introduced into the cardiovascular market in 2007. CARDIONOVUM is commercializing its breakthrough and proprietary drug-transfer platform technology SAFEPAX, which is incorporated into the LEGFLOW® peripheral DCB, the RESTORE® coronary DCB, and now the APERTO® DCB which has been developed and CE-marked exclusively for the treatment of AV fistulas and shunt graft stenosis.